Cargando…
Rituximab treatment in rheumatoid arthritis: how does it work?
Treatment with the chimerical monoclonal antibody rituximab results in CD20-directed B cell depletion. Although this depletion is almost complete in the peripheral blood of nearly all patients with rheumatoid arthritis, a proportion of patients does not exhibit a clinical response. The paper by Nako...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003538/ https://www.ncbi.nlm.nih.gov/pubmed/20017888 http://dx.doi.org/10.1186/ar2852 |
_version_ | 1782193873253040128 |
---|---|
author | Boumans, Maria JH Tak, Paul P |
author_facet | Boumans, Maria JH Tak, Paul P |
author_sort | Boumans, Maria JH |
collection | PubMed |
description | Treatment with the chimerical monoclonal antibody rituximab results in CD20-directed B cell depletion. Although this depletion is almost complete in the peripheral blood of nearly all patients with rheumatoid arthritis, a proportion of patients does not exhibit a clinical response. The paper by Nakou and colleagues suggests that a decrease in CD19+CD27+ memory B cells in both peripheral blood and bone marrow precedes the clinical response to rituximab. This finding adds to the emerging evidence that lack of response to rituximab is associated with persistence of B lineage cells in specific body compartments. |
format | Text |
id | pubmed-3003538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30035382010-12-18 Rituximab treatment in rheumatoid arthritis: how does it work? Boumans, Maria JH Tak, Paul P Arthritis Res Ther Editorial Treatment with the chimerical monoclonal antibody rituximab results in CD20-directed B cell depletion. Although this depletion is almost complete in the peripheral blood of nearly all patients with rheumatoid arthritis, a proportion of patients does not exhibit a clinical response. The paper by Nakou and colleagues suggests that a decrease in CD19+CD27+ memory B cells in both peripheral blood and bone marrow precedes the clinical response to rituximab. This finding adds to the emerging evidence that lack of response to rituximab is associated with persistence of B lineage cells in specific body compartments. BioMed Central 2009 2009-11-24 /pmc/articles/PMC3003538/ /pubmed/20017888 http://dx.doi.org/10.1186/ar2852 Text en Copyright ©2009 BioMed Central Ltd |
spellingShingle | Editorial Boumans, Maria JH Tak, Paul P Rituximab treatment in rheumatoid arthritis: how does it work? |
title | Rituximab treatment in rheumatoid arthritis: how does it work? |
title_full | Rituximab treatment in rheumatoid arthritis: how does it work? |
title_fullStr | Rituximab treatment in rheumatoid arthritis: how does it work? |
title_full_unstemmed | Rituximab treatment in rheumatoid arthritis: how does it work? |
title_short | Rituximab treatment in rheumatoid arthritis: how does it work? |
title_sort | rituximab treatment in rheumatoid arthritis: how does it work? |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003538/ https://www.ncbi.nlm.nih.gov/pubmed/20017888 http://dx.doi.org/10.1186/ar2852 |
work_keys_str_mv | AT boumansmariajh rituximabtreatmentinrheumatoidarthritishowdoesitwork AT takpaulp rituximabtreatmentinrheumatoidarthritishowdoesitwork |